Journal of Clinical Pediatrics >
Clinical features and long-term prognosis of 25 patients with systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome
Received date: 2023-01-17
Online published: 2024-03-06
Objective To investigate the clinical features and long-term prognosis of systemic juvenile idiopathic arthritis (sJIA) complicated with macrophage activation syndrome (MAS). Methods The clinical data of sJIA children complicated with MAS treated from August 2014 to August 2020 were retrospectively analyzed. The sJIA children without MAS diagnosed and treated in the same period were classified as sJIA without MAS group. The clinical manifestations and long-term prognosis were compared between the two groups. Results The median onset age of the 25 patients (11 boys and 14 girls) in sJIA with MAS group was 5.8 (2.6-10.0) years. The median onset age of 38 patients (18 boys and 20 girls) in sJIA without MAS group was 7.0 (5.1-9.0) years. Twenty-one patients had MAS in the early stage of sJIA. Compared with the sJIA without MAS group, the incidence of hepatosplenomegaly, respiratory system involvement, central nervous system involvement and bleeding in the sJIA with MAS group was higher, and the difference was statistically significant (P<0.05). Methemoglobinemia was the most common abnormal laboratory index in sJIA patients with MAS (100%), followed by elevated aspartate aminotransferase (24 cases) and decreased fibrinogen (23 cases). All patients were treated with glucocorticoids, 22 with intravenous immunoglobulin and 22 with cyclosporin A. Tocilizumab was added to 11 patients, 4 of them were treated with tocilizumab within 2 to 3 weeks of MAS activity, and 7 were treated with tocilizumab when sJIA was still in an unstable state after MAS remission. The median follow-up time was 40.0 (26.5-60.5) months. The results of follow-up to August 31, 2022 showed that there were 11 cases of monophasic course, 5 cases of recurrent course, and 9 cases of persistent course in the sJIA with MAS group, and there was no statistically significant difference in long-term prognosis compared with the sJIA without MAS group (P>0.05). Growth retardation occurred in 4 sJIA children with MAS who received glucocorticoid therapy for a long duration. Hormonal cataract occurred in 3 sJIA children with MAS. Conclusions For sJIA children complicated with MAS, if early identification, effective treatment and standardized management can be given in time, the long-term prognosis is similar to that of children without MAS.
Ping LIU , Chunya JIANG , Lei WEI , Xiangli WANG , Yunfeng JIN , Yujie QING , Yani YANG , Cuihua LIU . Clinical features and long-term prognosis of 25 patients with systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome[J]. Journal of Clinical Pediatrics, 2024 , 42(3) : 218 -223 . DOI: 10.12372/jcp.2024.22e1773
[1] | Onel K, Rumsey DG, Shenoi S. Juvenile idiopathic arthritis treatment updates[J]. Rheum Dis Clin North Am, 2021, 47(4): 545-563. |
[2] | Lee JJY, Schneider R. Systemic juvenile idiopathic arthritis[J]. Pediatr Clin North Am, 2018, 65(4): 691-709. |
[3] | 李彩凤, 黄新翔, 王永福, 等. 幼年特发性关节炎诊疗规范[J]. 中华内科杂志, 2022, 61(2): 142-156. |
[4] | Barut K, Adrovic A, Sahin S, et al. Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: a single-center experience[J]. Int J Rheum Dis, 2019, 22(9): 1661-1669. |
[5] | Boyarchuk O, Kovalchuk T, Kovalchuk N, et al. Clinical variability of the systemic juvenile idiopathic arthritis course: literature review based on case series[J]. Reumatologia, 2020, 58(6): 436-443. |
[6] | Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001[J]. J Rheumatol, 2004, 31(2): 390-392. |
[7] | Ravelli A, Minoia F, Davì S, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism/American college of rheumatology/pediatric rheumatology international trials organisation collaborative initiative[J]. Arthritis Rheumatol, 2016, 68(3): 566-576. |
[8] | Tibaldi J, Pistorio A, Aldera E, et al. Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis[J]. Rheumatology (Oxford), 2020, 59(11): 3505-3514. |
[9] | Bojan A, Parvu A, Zsoldos IA, et al. Macrophage activation syndrome: a diagnostic challenge (Review)[J]. Exp Ther Med, 2021, 22(2): 904. |
[10] | Minoia F, Davì S, Horne A, et al. Dissecting the heterogeneity of mac-rophage activation syndrome complicating systemic juvenile idiopathic arthritis[J]. J Rheumatol, 2015, 42(6): 994-1001. |
[11] | Shimizu M. Macrophage activation syndrome in systemic juvenile idiopathic arthritis[J]. Immunol Med, 2021, 44(4): 237-245. |
[12] | Crayne CB, Albeituni S, Nichols KE, et al. The immunology of macrophage sctivation syndrome[J]. Front Immunol, 2019, 10: 119. |
[13] | Lotfy HM, Kandil ME, Issac MS, et al. MEFV mutations in Egyptian children with systemic-onset juvenile idiopathic arthritis[J]. Mol Diagn Ther, 2014, 18(5): 549-557. |
[14] | Alongi A, Naddei R, De Miglio L, et al. Macrophage activation syndrome in pediatrics[J]. Pediatr Allergy Immunol, 2020, 31 Suppl 24: 13-15. |
[15] | Gilboa M, Bornstein G, Ben-Zvi I, et al. Macrophage activation syndrome complicating rheumatic diseases in adults: case-based review[J]. Rheumatol Int, 2020, 40(4): 663-669. |
[16] | 中国医师协会儿科医师分会风湿免疫学组, 中国儿童免疫与健康联盟,《中国实用儿科杂志》编辑委员会. 儿童风湿性疾病相关巨噬细胞活化综合征诊断与治疗专家共识之一——总论篇[J]. 中国实用儿科杂志, 2020, 35(11): 825-831. |
[17] | Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy[J]. Nat Rev Rheumatol, 2016, 12(5): 259-268. |
[18] | 中华医学会儿科学分会风湿病学组, 中国医师协会风湿免疫科医师分会儿科学组, 海峡两岸医药卫生交流协会风湿免疫病学专业委员会儿童学组, 等. 全身型幼年特发性关节炎及合并巨噬细胞活化综合征诊疗专家共识(2022版)[J]. 中华实用儿科临床杂志, 2022, (20): 1539-1548. |
[19] | Phadke O, Rouster-Stevens K, Giannopoulos H, et al. Intravenous administration of anakinra in children with macrophage activation syndrome[J]. Pediatr Rheumatol Online J, 2021, 29; 19(1): 98. |
/
〈 |
|
〉 |